ClinicalTrials.gg
CompletedNCT02006719ACUpdated Oct 5, 2017Results posted

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

A Phase 2 interventional study of Collagenase Clostridium Histolyticum and Placebo in Adhesive Capsulitis and Frozen Shoulder, sponsored by Endo Pharmaceuticals. Completed at 46 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies in Bursitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Bursitis · United States.

Enrollment
4th of 41
322 · median 40
Started
2013
with 3 others
Phase 2
6 of 45
none open now
Registered
20th of 45
by date
Lead sponsor
4 of 45
Endo Pharmaceuticals

Among the 45 studies in Bursitis with a site in United States, this one is the 4th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2013, is one of 6 in phase 2, and was the 20th registered.

Bursitis

383 studies on the registry are indexed under Bursitis; 111 are open to participants now.

Browse Bursitis studies →

Open to participants now

4 of the 45 studies in Bursitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 64 Bursitis studies recruiting now, 17 (27%) set no upper age limit and 40 (63%) stop at 75 or younger; none take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Bursitis with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.

Read the detailed description

Study is a Phase 2b, double-blind, placebo-controlled study of the safety and efficacy of AA4500 for the treatment of adhesive capsulitis of the shoulder. To be eligible for treatment, a subject must have unilateral idiopathic adhesive capsulitis of the shoulder with restricted range of motion in the affected shoulder for at least 3 months but not more than 12 months. Subjects will be screened for study eligibility within 28 days before injection of study drug.

Approximately 300 adult women and men are to be enrolled in this study. Following screening and determination of study eligibility, subjects will be randomized 3:1 to receive 0.58 mg of AA4500 or placebo. Subjects will receive up to 3 injections of study drug. Each injection will be separated by a minimum of 21 days. Subjects will also be instructed in home shoulder exercises after the first injection.

03

Conditions studied

  • Adhesive Capsulitis
  • Frozen Shoulder

Keywords

  • Adhesive Capsulitis
  • Frozen Shoulder
  • Shoulder Range of Motion limitation
  • Shoulder Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral idiopathic adhesive capsulitis of one shoulder for at least 3 months but not more than 12 months (Frozen Stage)
  • Normal range of motion in the contralateral shoulder
  • Restricted active range of motion (AROM) in the affected shoulder defined as: a deficit of at least 60 degrees in total AROM in the affected shoulder as compared with the total AROM in the contralateral shoulder and a deficit of at least 30 degrees in AROM in at least one of the following planes as compared with the contralateral shoulder:

    • Forward flexion
    • Abduction
    • External rotation with the elbow up to 90 degrees abduction
    • Internal rotation with the elbow up to 90 degrees abduction

Exclusion criteria

Exclusion Criteria:

  • Has received treatment for adhesive capsulitis or is planning to receive treatment for adhesive capsulitis at any time during the study including but not limited to:

    • physical therapy or acupuncture within 2 weeks before the first injection of study drug
    • intra-articular or intrabursal injection(s) of lidocaine; suprascapular nerve blocks; , electroanalgesic and/or thermoanalgesic modalities within 1 month before the screening visit
    • intra-articular or intrabursal injection(s) of sodium hyaluronate and/or glenohumeral distension arthrography within 3 months before the screening visit
    • surgical intervention (including shoulder manipulation under anesthesia) at any time
  • Has any of the following conditions, as determined by investigator to be potentially confounding to the evaluation of safety and efficacy:

    • Adhesive capsulitis as a result of traumatic injury (ie, direct injury to the shoulder such as fracture of the humerus or clavicle immediately preceding the onset of this episode of adhesive capsulitis). Traumatic events in the past that are not temporally related to the onset of this episode of adhesive capsulitis would not necessarily exclude a subject from participating in the study.
    • Active subacromial impingement in the affected shoulder
    • Calcified tendonitis in the affected shoulder
    • Glenohumeral joint arthritis in the affected shoulder
    • Arthrosis of the affected shoulder
    • Chondrolysis of the affected shoulder
    • Subscapularis tendon rupture of the affected shoulder
    • Other rotator cuff injuries of the affected shoulder
    • Uncontrolled hypertension
    • Uncontrolled diabetes
    • Uncontrolled thyroid disease
    • History of thrombosis or post-thrombosis syndrome
    • Physical impairment that would preclude performing the protocol defined exercises
    • Active infection in area to be treated
    • neurological disease
    • Bleeding disorder
    • Chronic use of anticoagulation medications and the subject cannot be cleared medically to stop taking medication for 7 days prior to each injection. Less than or equal to 150 mg aspirin is allowed during the study.
    • Known active hepatitis A, B, or C
    • Other significant medical condition (eg, morbid obesity, cervical disc disease), which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  • Has received oral or intravenous steroids for any reason within 3 weeks before the screening visit
  • Has received an drug or treatment within 30 days before the first dose of study drug.
  • Has a known allergy to collagenase or any other of AA4500 or any other procedural medication.
  • Has, at any time, received collagenase for the treatment of adhesive capsulitis.
  • Is unable to undergo an x-ray or MRI () evaluation of the affected shoulder.
  • Is planning to be treated with commercial XIAFLEX at any time during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    Collagenase Clostridium Histolyticum

    Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.

    Biological: Collagenase Clostridium Histolyticum

  • Placebo comparator
    Placebo

    Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 95 in Active Forward Flexion

    Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder

    Time frame: Baseline, day 95

Secondary outcomes

  1. Change From Baseline to Day 95 in Adapted American Shoulder and Elbow Surgeons (ASES) Function Subscale

    Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation (United States adapted version).

    Time frame: Baseline, day 95

  2. Change From Baseline to Day 95 in Pain With Movement Using 11-point Numeric Rating Scale (NRS)

    Participant assessment of pain in response to "How bad is the pain upon movement of your affected shoulder at its worst in the last 24 hours?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be.

    Time frame: Baseline, day 95

  3. Change From Baseline to Day 95 in Active Abduction

    AROM measurement using a goniometer to assess abduction in the affected shoulder

    Time frame: Baseline, day 95

  4. Change From Baseline to Day 95 in Passive Forward Flexion

    Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder

    Time frame: Baseline, day 95

  5. Change From Baseline to Day 95 in Passive Abduction

    PROM measurement using a goniometer to assess abduction in the affected shoulder

    Time frame: Baseline, day 95

  6. Change From Baseline to Day 95 in Active Internal Rotation

    AROM measurement using a goniometer to assess internal rotation in the affected shoulder

    Time frame: Baseline, day 95

  7. Change From Baseline to Day 95 in Active External Rotation

    AROM measurement using a goniometer to assess external rotation in the affected shoulder

    Time frame: Baseline, day 95

  8. Change From Baseline to Day 95 in Passive Internal Rotation

    PROM measurement using a goniometer to assess internal rotation in the affected shoulder

    Time frame: Baseline, day 95

  9. Change From Baseline to Day 95 in Passive External Rotation

    PROM measurement using a goniometer to assess external rotation in the affected shoulder

    Time frame: Baseline, day 95

  10. Change From Baseline to Day 95 in Adapted ASES Pain Subscale

    Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant overall assessment of pain in response to "How bad is the pain in your affected shoulder today?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5; adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

    Time frame: Baseline, day 95

  11. Subject Satisfaction With Treatment at Day 95

    Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.

    Time frame: Day 95

  12. Investigator Assessment of Improvement With Treatment at Day 95

    Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

    Time frame: Day 95

07

Results

Posted May 25, 2017

Participant flow

Participant flow — Overall Study
MilestoneAA4500Placebo
Started23785
Completed21980
Not completed185
Withdrew: Withdrawal by subject102
Withdrew: Lost to follow-up51
Withdrew: Protocol violation20
Withdrew: Adverse event11
Withdrew: Other/unknown01

Outcome measures

PrimaryChange From Baseline to Day 95 in Active Forward Flexion

Active range of motion (AROM) measurement using a goniometer to assess forward flexion in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Active Forward Flexion
degreesAA4500Placebo
Change From Baseline to Day 95 in Active Forward Flexion41.0 ± 28.8935.9 ± 23.36
SecondaryChange From Baseline to Day 95 in Adapted American Shoulder and Elbow Surgeons (ASES) Function Subscale

Function subscale score ranging from 0-50, with 0 being most dysfunctional, derived from participant assessment of ability to do 10 activities with affected shoulder/arm where 0=unable to do to, 1=very difficult to do, 2=somewhat difficult, and 3=not difficult, and calculated as (cumulative total score for the 10 activity items) × (5/3); adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation (United States adapted version).

Time frame:
Baseline, day 95
Reported as:
Mean · units on a scale
Change From Baseline to Day 95 in Adapted American Shoulder and Elbow Surgeons (ASES) Function Subscale
units on a scaleAA4500Placebo
Change From Baseline to Day 95 in Adapted American Shoulder and Elbow Surgeons (ASES) Function Subscale17.0 ± 11.6514.8 ± 11.14
SecondaryChange From Baseline to Day 95 in Pain With Movement Using 11-point Numeric Rating Scale (NRS)

Participant assessment of pain in response to "How bad is the pain upon movement of your affected shoulder at its worst in the last 24 hours?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be.

Time frame:
Baseline, day 95
Reported as:
Mean · units on a scale
Change From Baseline to Day 95 in Pain With Movement Using 11-point Numeric Rating Scale (NRS)
units on a scaleAA4500Placebo
Change From Baseline to Day 95 in Pain With Movement Using 11-point Numeric Rating Scale (NRS)-4.4 ± 2.83-3.9 ± 2.93
SecondaryChange From Baseline to Day 95 in Active Abduction

AROM measurement using a goniometer to assess abduction in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Active Abduction
degreesAA4500Placebo
Change From Baseline to Day 95 in Active Abduction49.0 ± 33.1043.8 ± 30.71
SecondaryChange From Baseline to Day 95 in Passive Forward Flexion

Passive range of motion (PROM) measurement using a goniometer to assess forward flexion in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Passive Forward Flexion
degreesAA4500Placebo
Change From Baseline to Day 95 in Passive Forward Flexion39.3 ± 29.4734.1 ± 22.37
SecondaryChange From Baseline to Day 95 in Passive Abduction

PROM measurement using a goniometer to assess abduction in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Passive Abduction
degreesAA4500Placebo
Change From Baseline to Day 95 in Passive Abduction45.4 ± 33.6942.8 ± 32.12
SecondaryChange From Baseline to Day 95 in Active Internal Rotation

AROM measurement using a goniometer to assess internal rotation in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Active Internal Rotation
degreesAA4500Placebo
Change From Baseline to Day 95 in Active Internal Rotation23.1 ± 25.2120.9 ± 23.58
SecondaryChange From Baseline to Day 95 in Active External Rotation

AROM measurement using a goniometer to assess external rotation in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Active External Rotation
degreesAA4500Placebo
Change From Baseline to Day 95 in Active External Rotation28.6 ± 21.3026.1 ± 22.67
SecondaryChange From Baseline to Day 95 in Passive Internal Rotation

PROM measurement using a goniometer to assess internal rotation in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Passive Internal Rotation
degreesAA4500Placebo
Change From Baseline to Day 95 in Passive Internal Rotation24.1 ± 23.7720.3 ± 23.61
SecondaryChange From Baseline to Day 95 in Passive External Rotation

PROM measurement using a goniometer to assess external rotation in the affected shoulder

Time frame:
Baseline, day 95
Reported as:
Mean · degrees
Change From Baseline to Day 95 in Passive External Rotation
degreesAA4500Placebo
Change From Baseline to Day 95 in Passive External Rotation24.8 ± 22.3124.4 ± 26.16
SecondaryChange From Baseline to Day 95 in Adapted ASES Pain Subscale

Pain subscale score ranging from 0-50, with 0 being greatest pain, derived from participant overall assessment of pain in response to "How bad is the pain in your affected shoulder today?" using an 11-point NRS where 0=no pain at all and 10=pain as bad as it can be and calculated as (10 - NRS score) x 5; adapted from ASES Standardized Shoulder Assessment Form, Patient Self-Evaluation

Time frame:
Baseline, day 95
Reported as:
Mean · units on a scale
Change From Baseline to Day 95 in Adapted ASES Pain Subscale
units on a scaleAA4500Placebo
Change From Baseline to Day 95 in Adapted ASES Pain Subscale15.9 ± 13.4613.5 ± 13.45
SecondarySubject Satisfaction With Treatment at Day 95

Participant assessment of satisfaction with treatment rated as very satisfied, quite satisfied, neither satisfied nor dissatisfied, quite dissatisfied, or very dissatisfied.

Time frame:
Day 95
Reported as:
Number · participants
Subject Satisfaction With Treatment at Day 95
participantsAA4500Placebo
Very satisfied14243
Quite satisfied3822
Neither satisfied nor dissatisfied328
Quite dissatisfied102
Very dissatisfied76
SecondaryInvestigator Assessment of Improvement With Treatment at Day 95

Investigator assessment of degree of improvement in severity of the participant's treated shoulder compared with screening rated as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

Time frame:
Day 95
Reported as:
Number · participants
Investigator Assessment of Improvement With Treatment at Day 95
participantsAA4500Placebo
Very much improved9427
Much improved7331
Minimally improved4116
No change138
Minimally worse60
Much worse10
Very much worse10

Adverse events

Collected over 130 days (up to 28 day screening period and 95±7 day study period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500—4/237 (1.7%)188/237 (79.3%)
Placebo—1/84 (1.2%)37/84 (44%)
Most frequent serious events
Most frequent serious events
EventAA4500Placebo
Gastric ulcerGastrointestinal disorders0/2371/84
Atrial fibrilationCardiac disorders1/2370/84
GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2370/84
OverdoseInjury, poisoning and procedural complications1/2370/84
Post procedural bile leakInjury, poisoning and procedural complications1/2370/84
Procedural painInjury, poisoning and procedural complications1/2370/84
Most frequent other events
Most frequent other events
EventAA4500Placebo
Musculoskeletal painMusculoskeletal and connective tissue disorders90/23718/84
ContusionInjury, poisoning and procedural complications71/2372/84
Injection site bruisingGeneral disorders52/23710/84
Injection site painGeneral disorders50/23711/84
EcchymosisSkin and subcutaneous tissue disorders47/2373/84
Localised oedemaGeneral disorders20/2371/84
Pain in extremityMusculoskeletal and connective tissue disorders13/2374/84
PruritusSkin and subcutaneous tissue disorders12/2370/84

Baseline characteristics

All participants who received at least 1 administration of study drug (1 participant excluded)

Age, Continuous
Age, Continuous(years)AA4500PlaceboTotal
Median53.0 (29 to 75)51.0 (22 to 70)52.0 (22 to 75)
Age, Customized
Age, Customized(Participants)AA4500PlaceboTotal
<45301444
45-5411444158
55-64752398
65-7417320
≥75101
Sex: Female, Male
Sex: Female, Male(Participants)AA4500PlaceboTotal
Female16260222
Male752499
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AA4500PlaceboTotal
Hispanic or Latino17421
Not Hispanic or Latino22080300
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AA4500PlaceboTotal
American Indian or Alaska Native011
Asian6410
Native Hawaiian or Other Pacific Islander202
Black or African American22729
White20572277
More than one race101
Unknown or Not Reported101
08

Study locations

46 sites
  • Alabama Orthopaedic Center-Research
    Birmingham, Alabama 35209, United States
  • Coastal Clinical Research
    Mobile, Alabama 36608, United States
  • Arizona Research Center, Inc.
    Phoenix, Arizona 85023, United States
  • Advance Med Clinical Research
    Carlsbad, California 92008, United States
  • Triwest Research Associates
    El Cajon, California 92020, United States
  • Core Orthopedic Medical Center
    Encinitas, California 92024, United States
  • Temecula Rheumatology & Internal Medicine
    Murrieta, California 92563, United States
  • Clearview Medical Research
    Santa Clarita, California 91350, United States
  • Colorado Orthopedic Consultants, PC
    Englewood, Colorado 80110, United States
  • Florida Research Associates
    DeLand, Florida 32720, United States
  • Shrock Orthopedic Research, LLC
    Fort Lauderdale, Florida 33316, United States
  • Jewett Orthopedic Clinic
    Orlando, Florida 32822, United States
  • Clinical Research of West Florida
    Tampa, Florida 33603, United States
  • Non-Surgical Orthopedics, P.C. / Georgia Institute for Clinical Research, LLC
    Marietta, Georgia 30060, United States
  • Injury Care Medical Center
    Boise, Idaho 83713, United States
  • Rockford Orthopedic Associates
    Rockford, Illinois 61107, United States
  • Rockford Orthopedics Associates
    Rockford, Illinois 61114, United States
  • Indiana Hand to Shoulder Center
    Indianapolis, Indiana 46260, United States
  • PRN of Kansas
    Wichita, Kansas 67203, United States
  • Central Kentucky Research Associates
    Lexington, Kentucky 40509, United States
  • Bone and Joint Clinic
    Gretna, Louisiana 70056, United States
  • MedPharmics, LLC
    Metairie, Louisiana 70006, United States
  • Arthritis and Rheumatism Associates, PC
    Wheaton, Maryland 20902, United States
  • Great Falls Clinic
    Great Falls, Montana 59405, United States
  • Nevada Orthopedic & Spine Center
    Las Vegas, Nevada 89128, United States
  • Stony Brook University Medical Center (SUNY)
    Stony Brook, New York 11794, United States
  • Triangle Orthopedic Associates, PA
    Durham, North Carolina 27704, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • The Neuromusculoskeletal Center of the Cascades d.b.a. The Center
    Bend, Oregon 97701, United States
  • Blair Orthopedic Associates, Inc.
    Altoona, Pennsylvania 16602, United States
  • University of Pennsylvania Penn Orthopaedics
    Philadelphia, Pennsylvania 19087, United States
  • Texas Orthopedic Specialist
    Bedford, Texas 76021, United States
  • Centex Studies
    Houston, Texas 77062, United States
  • Commonwealth Orthopaedics & Rehabilitation
    Arlington, Virginia 22205, United States
  • Danville Orthopedic Clinic, Inc.
    Danville, Virginia 24541, United States
  • Sports Medicine Professionals
    Richmond, Victoria 3121, Australia
  • Hunter Clinical Research
    NSW, Australia
  • Royal Prince Alfred
    NSW, Australia
  • St George Hospital
    NSW, Australia
  • Peninsula Private Hospital
    Queensland, Australia
  • QPharm
    Queensland, Australia
  • Menzies Research Institute
    Tasmania, Australia
  • Emeritus Research
    VIC, Australia
  • Epworth Hospital
    VIC, Australia
  • Repatriation Hospital
    VIC, Australia
  • Hand and Upper Limb Centre
    WA, Australia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 2 years 5 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2013
First posted
Dec 10, 2013
Start
Nov 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results delay requested
Mar 17, 2015
Results first posted
May 25, 2017
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02006719
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Nov 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
May 25, 2017
Last update
Oct 5, 2017

Study contacts

Neil H Schusterman, MD FACP
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion